RECIST 1.1与Choi标准在舒尼替尼治疗胃肠胰神经内分泌肿瘤早期疗效评估的比较.

Objective The aim of this study was to compare the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) and the Choi criteria for evaluating the early response of advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) to sunitinib therapy. Methods 18 patients with pathologically proven advanced GEP-NENs treated with sunitinib were enrolled in the study. Pre - and post -treatment unenhanced and bi -phasic contrast -enhanced CT was performed on all patients. Changes in the target tumor size and density from pre-treatment to 1.4-3.1 months after treatment were measured for each patient. Tumor responses were identified using the RECIST 1.1 and Choi criteria. The time to tumor progression (TTP) for each patient was measured and compared between groups using the Kaplan-Meier method. Results The treatment responses using the RECIST 1.1 were partial response (PR) in 4/18 (22%), stable disease (SD) in 9/18 (50%), and progressive disease (PD) in 5/18 (28%). The median TTP of the PR group (16.6 months) was significantly longer (P=0.007) than that of the PD group (2.3 months) and not significantly longer (P=0.131) than that of the SD group (10.8 months). Using the Choi criteria, treatment responses were PR (8/18, 44%), SD (4/18, 22%), and PD (6/18, 33%). According to Choi criteria, the median TTP of PR, SD and PD group were not reached, 10.8 and 2.3 months, respectively. The median TTP of the PR group was not reached and significantly longer (P=0.026) than that of the SD (10.8 months) and PD groups (2.3 months, P<0.001). Conclusion The Choi criteria appear to be more sensitive and precise than RECIST 1.1 for assessing the early response of advanced GEP-NENs to sunitinib therapy. [ABSTRACT FROM AUTHOR]